Astroglial expression of human α1-antichymotrypsin enhances Alzheimer-like pathology in amyloid protein precursor transgenic mice

American Journal of Pathology

Volumn 157, Issue 6, 2000, Pages 2003-2010

  Mucke, Lennart ^a   Yu, Gui Qiu ^a   McConlogue, Lisa ^b   Rockenstein, Edward M ^c   Abraham, Carmela R ^d   Masliah, Eliezer ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ELAN PHARMACEUTICALS   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; AMYLOID PRECURSOR PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL TISSUE; ARTICLE; AUTOSOMAL DOMINANT DISORDER; COMPLEMENT ACTIVATION; DENTATE GYRUS; HIPPOCAMPUS; HISTOPATHOLOGY; MACROGLIA; MOUSE; NEUROTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SYNAPTIC TRANSMISSION;

EID: 0033635193     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64839-0     Document Type: Article

References (60)

1. 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease
2. Alpha1-antichymotrypsin is present in diffuse senile plaques. A comparative study of beta-protein and alpha1-antichymotrypsin immunostaining in the Alzhelmer brain
3. Indicator expression directed by regulatory sequences of the glial fibrillary acidic protein (GFAP) gene: In vivo comparison of distinct GFAP-lacZ transgenes
4. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models
5. 1-42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation
6. Translating cell biology into therapeutic advances in Alzheimer's disease
7. The amyloid precursor protein of Alzheimer's disease and the Aβ peptide
8. Intracellular APP processing and Aβ production in Alzheimer disease
9. Generation and regulation of beta-amyloid peptide variants by neurons
10. Evidence that Aβ42 is the real culprit in Alzheimer's disease
11. Quantification of modified amyloid β peptides in Alzheimer disease and Down-syndrome brains
12. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
13. Levels and alternative splicing of amyloid β protein precursor (APP) transcripts in brains of transgenic mice and humans with Alzheimer's disease
14. Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F β-amyloid precursor protein and Alzheimer's disease
15. 42 deposition in a transgenic mouse model of Alzheimer disease
16. Mutant genes in familial Alzheimer's disease and transgenic models
17. Relative efficacies of amyloid β peptide (Aβ) binding proteins in Aβ aggregation
18. α1-antichymotrypsin is associated solely with amyloid deposits containing the β-protein. Amyloid and cell localization of α1-antichymotrypsin
19. The serpin superfamily of proteinase inhibitors: Structure, function, and regulation
20. 1-antichymotrypsin mRNA
21. Developmental expression of alpha1-antichymotrypsin in brain may be related to astrogliosis
22. Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments
23. A specific structural interaction of Alzheimer's peptide 65 β1-42 with α1-antichymotrypsin
24. 1-Antichymotrypsin binding to Alzheimer Aβ peptides is sequencespecific and induces fibril disaggregation in vitro
25. 1-antichymotrypsin regulates Alzheimer β-amyloid peptide fibril formation
26. 2-macroglobulin associates with β-amyloid peptide and prevents fibril formation
27. Alzheimer Aβ neurotoxicity: Promotion by antichymotrypsin, apoE4; inhibition by Aβ-related peptides
28. α1-antichymotrypsin interaction with Aβ(1-42) does not inhibit fibril formation but attenuates the peptide toxicity
29. α-1-Antichymotrypsin interaction with Aβ (1-40) inhibits fibril formation but does not affect the peptide toxicity
30. Serpins inhibit the toxicity of amyloid peptides
31. Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice
32. Elimination of the class A scavenger receptor does not affect amyloid plaque formation or neurodegeneration in transgenic mice expressing human amyloid protein precursors
33. Increased central nervous system production of extracellular matrix components and development of hydrocephalus in transgenic mice overexpressing transforming growth factor-β1
34. Amyloidogenic role of cytokine TGF-β1 in transgenic mice and Alzheimer's disease
35. Characterization of new polyclonal antibodies specific for 40 and 42 amino acid-long amyloid β peptides: Their use to examine the cell biology of presenilins and the immunohistochemistry of sporadic Alzheimer's disease and cerebral amyloid angiopathy cases
36. Synaptotrophic effects of human amyloid β protein precursor in the cortex of transgenic mice
37. Expression of human apolipoprotein E3 or E4 in the brains of Apoe(-/-) mice: Isoform-specific effects on neurodegeneration
38. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment
39. Regional synaptic pathology in Alzheimer's disease
40. Synaptic and neuritic alterations during the progression of Alzheimer's disease
41. Correlations of synaptic and pathological markers with cognition of the elderly
42. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease
43. Reactive synaptogenesis assessed by synaptophysin immunoreactivity is associated with GAP43 in the dentate gyrus of the adult rat
44. Distribution pattern and functional state of α1-antichymotrypsin in plaques and vascular amyloid in Alzheimer's disease
45. 1-antichymotrypsin and transforms it from inhibitor to substrate
46. An important role of heparan sulfate proteoglycan (perlecan) in a model system for the deposition and persistence of fibrillar a β-amyloid in rat brain
47. Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid
48. Metalloendopeptidase EC 3.4.24.15 is necessary for Alzheimer's amyloid-β peptide degradation
49. Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
50. TGF-β1 modulates brain amyloid deposition and induces Alzheimer's disease like microvascular abnormalities in transgenic mice
51. β-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease
52. The pathogenesis of Alzheimer disease: An alternative to the amyloid hypothesis
53. The mean Aβ load in the hippocampus correlates with duration and severity of dementia in subgroups of Alzheimer disease
54. The 'amyloid cascade hypothesis' of AD: Decoy or real McCoy?
55. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
56. Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease
57. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease
58. Aβ associated neuropil changes: Correlation with neuronal loss and dementia
59. Plaque-induced neurite abnormalities: Implications for disruption of neural networks in Alzheimer's disease
60. Inflammation and Alzheimer's disease. Neuroinflammation working group